Oxidative Stress in Schizophrenia
Increasing evidence indicates that oxidative damage exists in schizophrenia. Available literature about possible mechanisms of oxidative stress induction was reviewed. Furthermore, possibilities of measuring biomarkers of schizophrenia outside the central nervous system compartment, their specificit...
Gespeichert in:
Veröffentlicht in: | Current neuropharmacology 2011-06, Vol.9 (2), p.301-312 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 312 |
---|---|
container_issue | 2 |
container_start_page | 301 |
container_title | Current neuropharmacology |
container_volume | 9 |
creator | Grabnar, Iztok Vovk, Tomas Kores Plesnicar, Blanka Boskovic, Marija |
description | Increasing evidence indicates that oxidative damage exists in schizophrenia. Available literature about possible mechanisms of oxidative stress induction was reviewed. Furthermore, possibilities of measuring biomarkers of schizophrenia outside the central nervous system compartment, their specificity for different types of schizophrenia and potential therapeutic strategies to prevent oxidative injuries in schizophrenia were discussed. Data were extracted from published literature found in Medline, Embase, Biosis, Cochrane and Web of Science, together with hand search of references. Search terms were: schizophrenia, oxidative stress, antipsychotics, antioxidants and fatty acids. Finding a sensitive, specific and non invasive biomarker of schizophrenia, which could be measured in peripheral tissue, still stays an important task. Antioxidant enzymes, markers of lipid peroxidation, oxidatively modified proteins and DNA are most commonly used. As it considers the supplemental therapy, according to our meta-analysis vitamin E could potentially improve tardive dyskinesia, while for the effect of therapy with polyunsaturated fatty acids there is no clear evidence. Oxidative stress is a part of the pathology in schizophrenia and appears as a promising field to develop new therapeutic strategies. There is a need for well designed, placebo controlled trials with supplementation therapy in schizophrenia. |
doi_str_mv | 10.2174/157015911795596595 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3131721</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>908006455</sourcerecordid><originalsourceid>FETCH-LOGICAL-b524t-8c40ec228d7f0d629ab4b1985d18dc6e184880d61d8b59ac5ef18dc971baf3763</originalsourceid><addsrcrecordid>eNplkEFv1DAQhS1ERcvCH-CAlhOngO3EsX1BQlWhSJV6KEi9jRxnsjEkTrCdXeDIL69X265APXnk972ZN0PIK0bfcSar90xIyoRmTGohdC20eELOmJKiqJmmT3OdgSITt6fkeYzfKeVCcfmMnHLOSqZLfUbeXP9yrUlui-ubFDDGtfPrG9u7P9PcB_TOvCAnnRkivrx_V-Tbp4uv55fF1fXnL-cfr4pG8CoVylYULeeqlR1ta65NUzVMK9Ey1doamaqUygJrVSO0sQK7vaAla0xXyrpckQ-HvvPSjNha9CmYAebgRhN-w2Qc_K9418Nm2kKZd5F5oRV5e98gTD8XjAlGFy0Og_E4LRE0VZTWlRCZ5AfShinGgN1xCqOwPy08Pm02vf4339HycMsM_D0ATQ7YmzFah97iEexTmmG32wEuAX-YiAPaBHYaYZrRL2HItU_ZC3M_wwZ9QDAhOTsguBj9Q6hb2E7DMiLo_feCwCHOZoNQUlbeAZzbprA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>908006455</pqid></control><display><type>article</type><title>Oxidative Stress in Schizophrenia</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Grabnar, Iztok ; Vovk, Tomas ; Kores Plesnicar, Blanka ; Boskovic, Marija</creator><creatorcontrib>Grabnar, Iztok ; Vovk, Tomas ; Kores Plesnicar, Blanka ; Boskovic, Marija</creatorcontrib><description>Increasing evidence indicates that oxidative damage exists in schizophrenia. Available literature about possible mechanisms of oxidative stress induction was reviewed. Furthermore, possibilities of measuring biomarkers of schizophrenia outside the central nervous system compartment, their specificity for different types of schizophrenia and potential therapeutic strategies to prevent oxidative injuries in schizophrenia were discussed. Data were extracted from published literature found in Medline, Embase, Biosis, Cochrane and Web of Science, together with hand search of references. Search terms were: schizophrenia, oxidative stress, antipsychotics, antioxidants and fatty acids. Finding a sensitive, specific and non invasive biomarker of schizophrenia, which could be measured in peripheral tissue, still stays an important task. Antioxidant enzymes, markers of lipid peroxidation, oxidatively modified proteins and DNA are most commonly used. As it considers the supplemental therapy, according to our meta-analysis vitamin E could potentially improve tardive dyskinesia, while for the effect of therapy with polyunsaturated fatty acids there is no clear evidence. Oxidative stress is a part of the pathology in schizophrenia and appears as a promising field to develop new therapeutic strategies. There is a need for well designed, placebo controlled trials with supplementation therapy in schizophrenia.</description><identifier>ISSN: 1570-159X</identifier><identifier>EISSN: 1875-6190</identifier><identifier>DOI: 10.2174/157015911795596595</identifier><identifier>PMID: 22131939</identifier><language>eng</language><publisher>United Arab Emirates: Bentham Science Publishers Ltd</publisher><ispartof>Current neuropharmacology, 2011-06, Vol.9 (2), p.301-312</ispartof><rights>2011 Bentham Science Publishers Ltd 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b524t-8c40ec228d7f0d629ab4b1985d18dc6e184880d61d8b59ac5ef18dc971baf3763</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131721/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131721/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22131939$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Grabnar, Iztok</creatorcontrib><creatorcontrib>Vovk, Tomas</creatorcontrib><creatorcontrib>Kores Plesnicar, Blanka</creatorcontrib><creatorcontrib>Boskovic, Marija</creatorcontrib><title>Oxidative Stress in Schizophrenia</title><title>Current neuropharmacology</title><addtitle>CN</addtitle><description>Increasing evidence indicates that oxidative damage exists in schizophrenia. Available literature about possible mechanisms of oxidative stress induction was reviewed. Furthermore, possibilities of measuring biomarkers of schizophrenia outside the central nervous system compartment, their specificity for different types of schizophrenia and potential therapeutic strategies to prevent oxidative injuries in schizophrenia were discussed. Data were extracted from published literature found in Medline, Embase, Biosis, Cochrane and Web of Science, together with hand search of references. Search terms were: schizophrenia, oxidative stress, antipsychotics, antioxidants and fatty acids. Finding a sensitive, specific and non invasive biomarker of schizophrenia, which could be measured in peripheral tissue, still stays an important task. Antioxidant enzymes, markers of lipid peroxidation, oxidatively modified proteins and DNA are most commonly used. As it considers the supplemental therapy, according to our meta-analysis vitamin E could potentially improve tardive dyskinesia, while for the effect of therapy with polyunsaturated fatty acids there is no clear evidence. Oxidative stress is a part of the pathology in schizophrenia and appears as a promising field to develop new therapeutic strategies. There is a need for well designed, placebo controlled trials with supplementation therapy in schizophrenia.</description><issn>1570-159X</issn><issn>1875-6190</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNplkEFv1DAQhS1ERcvCH-CAlhOngO3EsX1BQlWhSJV6KEi9jRxnsjEkTrCdXeDIL69X265APXnk972ZN0PIK0bfcSar90xIyoRmTGohdC20eELOmJKiqJmmT3OdgSITt6fkeYzfKeVCcfmMnHLOSqZLfUbeXP9yrUlui-ubFDDGtfPrG9u7P9PcB_TOvCAnnRkivrx_V-Tbp4uv55fF1fXnL-cfr4pG8CoVylYULeeqlR1ta65NUzVMK9Ey1doamaqUygJrVSO0sQK7vaAla0xXyrpckQ-HvvPSjNha9CmYAebgRhN-w2Qc_K9418Nm2kKZd5F5oRV5e98gTD8XjAlGFy0Og_E4LRE0VZTWlRCZ5AfShinGgN1xCqOwPy08Pm02vf4339HycMsM_D0ATQ7YmzFah97iEexTmmG32wEuAX-YiAPaBHYaYZrRL2HItU_ZC3M_wwZ9QDAhOTsguBj9Q6hb2E7DMiLo_feCwCHOZoNQUlbeAZzbprA</recordid><startdate>201106</startdate><enddate>201106</enddate><creator>Grabnar, Iztok</creator><creator>Vovk, Tomas</creator><creator>Kores Plesnicar, Blanka</creator><creator>Boskovic, Marija</creator><general>Bentham Science Publishers Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201106</creationdate><title>Oxidative Stress in Schizophrenia</title><author>Grabnar, Iztok ; Vovk, Tomas ; Kores Plesnicar, Blanka ; Boskovic, Marija</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b524t-8c40ec228d7f0d629ab4b1985d18dc6e184880d61d8b59ac5ef18dc971baf3763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grabnar, Iztok</creatorcontrib><creatorcontrib>Vovk, Tomas</creatorcontrib><creatorcontrib>Kores Plesnicar, Blanka</creatorcontrib><creatorcontrib>Boskovic, Marija</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current neuropharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grabnar, Iztok</au><au>Vovk, Tomas</au><au>Kores Plesnicar, Blanka</au><au>Boskovic, Marija</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oxidative Stress in Schizophrenia</atitle><jtitle>Current neuropharmacology</jtitle><addtitle>CN</addtitle><date>2011-06</date><risdate>2011</risdate><volume>9</volume><issue>2</issue><spage>301</spage><epage>312</epage><pages>301-312</pages><issn>1570-159X</issn><eissn>1875-6190</eissn><abstract>Increasing evidence indicates that oxidative damage exists in schizophrenia. Available literature about possible mechanisms of oxidative stress induction was reviewed. Furthermore, possibilities of measuring biomarkers of schizophrenia outside the central nervous system compartment, their specificity for different types of schizophrenia and potential therapeutic strategies to prevent oxidative injuries in schizophrenia were discussed. Data were extracted from published literature found in Medline, Embase, Biosis, Cochrane and Web of Science, together with hand search of references. Search terms were: schizophrenia, oxidative stress, antipsychotics, antioxidants and fatty acids. Finding a sensitive, specific and non invasive biomarker of schizophrenia, which could be measured in peripheral tissue, still stays an important task. Antioxidant enzymes, markers of lipid peroxidation, oxidatively modified proteins and DNA are most commonly used. As it considers the supplemental therapy, according to our meta-analysis vitamin E could potentially improve tardive dyskinesia, while for the effect of therapy with polyunsaturated fatty acids there is no clear evidence. Oxidative stress is a part of the pathology in schizophrenia and appears as a promising field to develop new therapeutic strategies. There is a need for well designed, placebo controlled trials with supplementation therapy in schizophrenia.</abstract><cop>United Arab Emirates</cop><pub>Bentham Science Publishers Ltd</pub><pmid>22131939</pmid><doi>10.2174/157015911795596595</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1570-159X |
ispartof | Current neuropharmacology, 2011-06, Vol.9 (2), p.301-312 |
issn | 1570-159X 1875-6190 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3131721 |
source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
title | Oxidative Stress in Schizophrenia |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T20%3A09%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oxidative%20Stress%20in%20Schizophrenia&rft.jtitle=Current%20neuropharmacology&rft.au=Grabnar,%20Iztok&rft.date=2011-06&rft.volume=9&rft.issue=2&rft.spage=301&rft.epage=312&rft.pages=301-312&rft.issn=1570-159X&rft.eissn=1875-6190&rft_id=info:doi/10.2174/157015911795596595&rft_dat=%3Cproquest_pubme%3E908006455%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=908006455&rft_id=info:pmid/22131939&rfr_iscdi=true |